Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
 Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee
Patrick Enright 
Patrick Enright
Director


Patrick Enright is a founder and Managing Director of Longitude Capital. Previously, Mr. Enright was a Managing Director of Pequot Ventures. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis... 

  Chairperson Committee Member
Kathryn “Kate”  Falberg Financial Expert
Kathryn “Kate”  Falberg
Director


Kathryn “Kate” Falberg is Chair of the Audit Committee for the Aimmune Board of Directors and serves as a Board Member and Audit Committee Chair for several life sciences companies. Ms. Falberg currently serves as a Director and Chair of the Audit committee for publicly traded biotechnology companies Medivation, Inc., and Halozyme Therapeutics, where she is also Chairman of the Board, and privately held aTyr Pharma. She previously served on the boards of Ariosa Diagnostics, QLT, VISX, Fresh D... 

Chairperson Committee Member  
Mark Iwicki 
Mark Iwicki
Director


Mark Iwicki is Executive Chairman of the Board of Directors of Kala Pharmaceuticals and sits on the Boards of Nimbus Therapeutics and Taris Biomedical. He was President and CEO of Civitas Therapeutics until late 2014, when it was acquired by Acorda Therapeutics. Prior to joining Civitas, Mr. Iwicki was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He was also President and CEO of Sunovion Pharmaceuticals after leading its launch from the acquisition of Se... 

Committee Member   
Mark McDade 
Mark McDade
Chairman


Mark McDade is Chairman of the Aimmune Board of Directors and Executive Vice President and Chief Operating Officer of UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research. At UCB, Mr. McDade leads worldwide geographic operations, established brands, technical operations and business development. Previously, Mr. McDade served as CEO and as a Director of PDL Biopharma. He was also CEO of Signature Bioscience; Founder, Chief Operating Officer, Presi... 

  Committee Member Chairperson
Stacey D. Seltzer 
Stacey D. Seltzer
Director


Stacey Seltzer is a partner at Aisling Capital. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company. Ms. Seltzer serves as a director... 

Committee Member   Committee Member


  • Chairperson Chairperson
  • Committee Member Member
  • Financial Expert Financial Expert